Tezepelumab granted Priority Review by U.S. FDA
The Pharma Data
JULY 8, 2021
The FDA grants Priority Review to applications for medicines that offer significant advantages over available options by demonstrating safety or efficacy improvements, preventing serious conditions or enhancing patient compliance.(1) Results from the NAVIGATOR Phase 3 trial were published in the New England Journal of Medicine in May 2021.
52 
Let's personalize your content